OnKure Therapeutics (OKUR) Accounts Payables (2020 - 2026)

OnKure Therapeutics (OKUR) has reported Accounts Payables for 7 consecutive years, with $2.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accounts Payables fell 16.04% year-over-year to $2.0 million; the trailing twelve-month figure through Jun 2026 stood at $2.0 million (down 16.04% YoY), and the FY2025 full-year result was $1.4 million, down 51.72% from the prior year.
• Accounts Payables retreated to $2.0 million in Q2 2026 per OKUR's latest filing, from $11.0 million in the prior quarter.
• Across five years, Accounts Payables topped out at $11.0 million in Q1 2026 and bottomed at $64000.0 in Q2 2024.
• Historically, Accounts Payables has averaged $2.3 million across 5 years, with a median of $1.9 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables plunged 96.5% in 2024, then soared 3620.31% in 2025.
• Over 5 years, Accounts Payables stood at $1.9 million in 2022, then jumped by 80.51% to $3.4 million in 2023, then retreated by 13.14% to $3.0 million in 2024, then tumbled by 51.72% to $1.4 million in 2025, then soared by 39.5% to $2.0 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $2.0 million, $11.0 million, and $1.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.